Paper40977752
JAK Inhibitors for Treatment of VEXAS Syndrome: A Systematic Review of 186 Cases.
Bahramian S and 9 others. Dermatol Res Pract, 2025. Cited by 7 papers, by iCite.
Cite this record
ConductScience Library. JAK Inhibitors for Treatment of VEXAS Syndrome: A Systematic Review of 186 Cases. Papers, record 40977752. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40977752
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References53
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35597594 | Acute tubulointerstitial nephritis revealing VEXAS syndrome. | Kidney Int | 2022 | https://conductscience.org/library/papers/35597594 | PubMed |
| 2 | 36641501 | Successful azacitidine therapy for myelodysplastic syndrome associated with VEXAS syndrome. | Int J Hematol | 2023 | https://conductscience.org/library/papers/36641501 | PubMed |
| 3 | 38736269 | Safety and efficacy of tofacitinib in 97 alopecia areata patients. | J Cosmet Dermatol | 2024 | https://conductscience.org/library/papers/38736269 | PubMed |
| 4 | 40046741 | Efficacy and safety profile of biotechnological agents and Janus kinase inhibitors in VEXAS syndrome: data from the international AIDA Network VEXAS registry. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/40046741 | PubMed |
| 5 | 26432019 | UBA1: At the Crossroads of Ubiquitin Homeostasis and Neurodegeneration. | Trends Mol Med | 2015 | https://conductscience.org/library/papers/26432019 | PubMed |
| 6 | 40183135 | The Challenging and Unique Diagnosis of VEXAS Syndrome: A Case Report. | J Investig Med High Impact Case Rep | 2025 | https://conductscience.org/library/papers/40183135 | PubMed |
| 7 | 38398362 | VEXAS and Myelodysplastic Syndrome: An Interdisciplinary Challenge. | J Clin Med | 2024 | https://conductscience.org/library/papers/38398362 | PubMed |
| 8 | 40412417 | Treatment outcomes in patients with VEXAS syndrome: a retrospective cohort study. | Lancet Rheumatol | 2025 | https://conductscience.org/library/papers/40412417 | PubMed |
| 9 | 38333211 | Case report: Cytopenias in VEXAS syndrome - a WHO 2022 based approach in a single-center cohort. | Front Immunol | 2024 | https://conductscience.org/library/papers/38333211 | PubMed |
| 10 | 37247942 | JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications. | Ann Rheum Dis | 2023 | https://conductscience.org/library/papers/37247942 | PubMed |
| 11 | 34611997 | VEXAS Syndrome: A Case Series From a Single-Center Cohort of Italian Patients With Vasculitis. | Arthritis Rheumatol | 2022 | https://conductscience.org/library/papers/34611997 | PubMed |
| 12 | 37337622 | Tofacitinib as a biologic response modifier in VEXAS syndrome: A case series. | Int J Rheum Dis | 2023 | https://conductscience.org/library/papers/37337622 | PubMed |
| 13 | 40373272 | Efficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from FRENVEX. | Blood | 2025 | https://conductscience.org/library/papers/40373272 | PubMed |
| 14 | 37606963 | Efficient detection of somatic UBA1 variants and clinical scoring system predicting patients with variants in VEXAS syndrome. | Rheumatology (Oxford) | 2024 | https://conductscience.org/library/papers/37606963 | PubMed |
| 15 | 36150749 | Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis. | Ann Rheum Dis | 2023 | https://conductscience.org/library/papers/36150749 | PubMed |
| 16 | 39081801 | Long-term genetic and clinical remissions after cessation of azacitidine treatment in patients with VEXAS syndrome. | Hemasphere | 2024 | https://conductscience.org/library/papers/39081801 | PubMed |
| 17 | 35230710 | Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome: a presentation of two cases with dermatologic findings. | Int J Dermatol | 2023 | https://conductscience.org/library/papers/35230710 | PubMed |
| 18 | 37230920 | JAK-STAT pathway inhibitors in dermatology. | An Bras Dermatol | 2023 | https://conductscience.org/library/papers/37230920 | PubMed |
| 19 | 38473222 | JAK Inhibitors in Cutaneous T-Cell Lymphoma: Friend or Foe? A Systematic Review of the Published Literature. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/38473222 | PubMed |
| 20 | 33782057 | The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. | BMJ | 2021 | https://conductscience.org/library/papers/33782057 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42547647 | JAK inhibitor therapy in CANDLE syndrome: a systematic review of clinical outcomes in 46 patients. | Eur J Pediatr | 2026 | https://conductscience.org/library/papers/42547647 | PubMed |
| 42472066 | JAK Inhibitors for Treatment of Pyoderma Gangrenosum and Sweet Syndrome: A Systematic Review of Published Case Reports. | Dermatol Res Pract | 2026 | https://conductscience.org/library/papers/42472066 | PubMed |
| 42200825 | VEXAS Syndrome: Clinical Features, Hematologic Involvement, and Clinical Outcomes of Current and Emerging Therapies. | Hematol Rep | 2026 | https://conductscience.org/library/papers/42200825 | PubMed |
| 41953903 | Janus Kinase Inhibitors for Treatment of Palmoplantar Pustulosis, Generalized Pustular Psoriasis, and Palmoplantar Pustular Psoriasis: A Systematic Review of the Literature. | Health Sci Rep | 2026 | https://conductscience.org/library/papers/41953903 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40977752
GET https://conductscience.org/api/papers/v1/40977752/references?page=2